GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (STU:OND) » Definitions » Asset Turnover

Oncopeptides AB (STU:OND) Asset Turnover : 0.04 (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Oncopeptides AB Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Oncopeptides AB's Revenue for the three months ended in Dec. 2024 was €0.86 Mil. Oncopeptides AB's Total Assets for the quarter that ended in Dec. 2024 was €24.67 Mil. Therefore, Oncopeptides AB's Asset Turnover for the quarter that ended in Dec. 2024 was 0.04.

Asset Turnover is linked to ROE % through Du Pont Formula. Oncopeptides AB's annualized ROE % for the quarter that ended in Dec. 2024 was -348.12%. It is also linked to ROA % through Du Pont Formula. Oncopeptides AB's annualized ROA % for the quarter that ended in Dec. 2024 was -117.59%.


Oncopeptides AB Asset Turnover Historical Data

The historical data trend for Oncopeptides AB's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncopeptides AB Asset Turnover Chart

Oncopeptides AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.17 0.02 0.11 0.13

Oncopeptides AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.03 0.02 0.04

Competitive Comparison of Oncopeptides AB's Asset Turnover

For the Biotechnology subindustry, Oncopeptides AB's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncopeptides AB's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncopeptides AB's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Oncopeptides AB's Asset Turnover falls into.


;
;

Oncopeptides AB Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Oncopeptides AB's Asset Turnover for the fiscal year that ended in Dec. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=2.751/( (21.31+21.229)/ 2 )
=2.751/21.2695
=0.13

Oncopeptides AB's Asset Turnover for the quarter that ended in Dec. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=0.862/( (28.117+21.229)/ 2 )
=0.862/24.673
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Oncopeptides AB  (STU:OND) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Oncopeptides AB's annulized ROE % for the quarter that ended in Dec. 2024 is

ROE %**(Q: Dec. 2024 )
=Net Income/Total Stockholders Equity
=-29.012/8.334
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-29.012 / 3.448)*(3.448 / 24.673)*(24.673/ 8.334)
=Net Margin %*Asset Turnover*Equity Multiplier
=-841.42 %*0.1397*2.9605
=ROA %*Equity Multiplier
=-117.59 %*2.9605
=-348.12 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) net income data. The Revenue data used here is four times the quarterly (Dec. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Oncopeptides AB's annulized ROA % for the quarter that ended in Dec. 2024 is

ROA %(Q: Dec. 2024 )
=Net Income/Total Assets
=-29.012/24.673
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-29.012 / 3.448)*(3.448 / 24.673)
=Net Margin %*Asset Turnover
=-841.42 %*0.1397
=-117.59 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) net income data. The Revenue data used here is four times the quarterly (Dec. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Oncopeptides AB Asset Turnover Related Terms

Thank you for viewing the detailed overview of Oncopeptides AB's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncopeptides AB Business Description

Traded in Other Exchanges
Address
Vastra Tradgardsgatan 15, Stockholm, SWE, SE-111 53
Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Conjugate (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate Melflufen (Pepaxti), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and in particular multiple myeloma.

Oncopeptides AB Headlines